This week we’re taking an in-depth look at some of the most innovative new medical CBD products available on the market.
And did you know that younger people are more incline to take CBD instead of prescription medications? Also, we’re covering how to get the correct dose of CBD – which is an incredibly touchy topic – as well as a few recently discovered drug interactions with CBD. All that and more in this week’s Medical Cannabis Weekly Review and Newsletter.
As the CBD industry goes from zero to hero in just a few short years, more and more delivery systems for this natural plant compound are finding their way into the marketplace. One new, discreet, and extremely convenient way of taking CBD is via sublingual strips, which get CBD into the bloodstream bypassing the digestive system.
A recent study from EOS Scientific reveals that a growing number of millennials – adults between the ages of 18 and 34 – prefer CBD over prescription drugs for mental health disorders. The study looked at more than 2,000 adults in the UK who are seeking better treatment options for issues related to mental health.
While the CBD industry is growing in leaps and bounds, scientific research and studies remain lacking. One thing that nobody really has a clue about is what the right CBD dose is for which condition. For the time being, there are no specific guidelines which has patients feeling confused and frustrated.
Medicating with transdermal patches isn’t a new concept. It was invented and brought to market back in 1979 and has since proved itself to be an effective and efficient way to take various medications and supplements. CBD patches contain various concentrations of CBD, all contained inside a band-aid-style plaster which is stuck on the skin.
The theory that CBD can possibly interact with various medications has been thrown around for a while now, but as it turns out, some recently completed studies indicate this may be true. It’s a commonly held belief that because CBD is natural, it doesn’t have side effects or any negative drug interactions, but that’s a dangerous belief to have.
OTHER TRENDING NEWS
While the Republican party has traditionally held an anti-cannabis stance, the Senate committee just scheduled a hearing to discuss business banking access for cannabis companies. Cannabis is a hot topic of discussion this year and with elections coming up soon, you can expect politicians on both sides of the fence to be scrambling to find solutions for all these industry grey areas.
It’s possible that Novel Food CBD classification may well become the accepted legal position for European CBD industry. Many ‘smart’ companies are already going through the process of securing compliance. However, at a cost of upwards of £250,000 such a certification is not coming cheap.